Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants

Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Urinary incontinence means losing control of bladder that leads to involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost, and thus, a person urinates even when they do not want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra do not work in the way they should, and resulting in leak of urine. Urinary incontinence can be caused by everyday habits, underlying medical conditions, or physical problems. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per the health conditions such as urinary tract infection (UTI), constipation, and urinary incontinence . Urinary incontinence is found more in geriatric population.

Market Dynamics

Key players in the market are focusing on the development of cost efficient solutions. Thus, introduction of new and advanced products in the market is expected to drive growth of the global urinary incontinence treatment drugs market over the forecast period. For instance, on March 15, 2023, MSN Laboratories, a leading pharmaceutical company, announced the launch of Fesobig, the world's first bioequivalent generic version of fesoterodine fumarate. Fesobig is recommended by various international treatment guidelines for the treatment of overactive bladder (OAB) and urinary incontinence (UI), as the safest and novel first-line pharmacotherapy option. The company have ensured that the drug has an affordable price so that it can benefit a large majority of patients. As overactive bladder (OAB) is an involuntary loss of urine due to pelvic floor dysfunction, which is strongly associated with the female population. The prevalence of urinary incontinence in India is also relatively high, ranging from 10% in rural areas to 34% in urban areas. Although urinary incontinence is not a life-threatening condition, it causes discomfort, embarrassment and a loss of self-confidence.

Key features of the study:

• This report provides an in-depth analysis of the global urinary incontinence treatment drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global urinary incontinence treatment drugs market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Sanofi S.A., IXALTIS, Bayer AG, elicept Therapeutics, Taiho Pharmaceutical, Cook MyoSite and Urovant Sciences GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global urinary incontinence treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary incontinence treatment drugs market

Global Urinary Incontinence Treatment Drugs Market Detailed Segmentation:

• By Incontinence Type:
• Urge Incontinence
• Stress Incontinence
• Over-flow Incontinence
• Mixed Incontinence
• Other Incontinence Type
• By Drug Class:
• Anticholinergic/Antispasmodic Agents
• Skeletal Muscle Relaxants
• Antidepressants
• Alpha Blockers
• Topical Estrogens
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles
• Johnson & Johnson
• Pfizer Inc.
• Astellas Pharma, Inc.
• Allergan, Inc.
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Sanofi S.A.
• IXALTIS
• Bayer AG
• elicept Therapeutics
• Taiho Pharmaceutical
• Cook MyoSite
• Urovant Sciences GmbH